Detoxification treatments for opiate dependent adolescents
Referencias
Additional references
Australian Institute of Health and Welfare: 2005. 2004 National Drug Strategy Household Survey: Detailed Findings October 2005. AIHW cat. no. PHE 66. Canberra: AIHW (Drug Statistics Series No 16). Canberra: Australian Institute of Health and Welfare, 2005.
Altobelli E, Rapacchietta L, Tiberti S, Petrocelli R, Cicioni L, di Orio F, et al. Association between drug, alcohol and tabacco use in adolescents and socio‐familiar factors [Associazione tra l'uso di sostanze stupefacenti, alcol e tabacco negli adolescenti e contesto socio‐familiare]. Annali d'Igiene 2005;17:57‐65.
Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858]
Amato L, Davoli M, Minozzi S, Ali R, Ferri M. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858]
Chalmers I. The Cochrane collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care. Annals of the New York Academy of Sciences 1993;703:156‐63; discussion 163‐5.
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005].. The Cochrane Library. Issue 4, 2007.
Day E, Ison J, Strang J. Inpatient versus other settings for detoxification for opioid dependence. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.]
Dortmizer CM, Gonzalez GB, Penna M, Bejarano J, Obando P, Sanchez M, et al. The PACARDO research project: youthful drug involvement in Central Amrica and the Dominican Republic. Rev Panam Salud Publica 2004;15(6):400‐16.
European Monitoring Centre for Drugd & Drug Addiction (EMCDDA). Annual Report: The state of the drugs problem in European Union and Norway. Office for publications of the European Communities, Luxembourg2005.
Gossop M, Green L, Phillips G, Bradley B. Lapse, relapse and survival among opiate addicts after treatment. British Journal of Psychiatry 1989;154:348‐53.
Gowing L, Farrell M, Ali R, White J. Alpha2 adrenergic agonists for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858]
Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.]
Gowing L, Ali R, White J. Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.]
Gowing L, Ali R, White J. Opioid antagonists under heavy sedation or anaesthesia for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858]
Hopfer CJ, Khurl E, Crowley TJ, Hooks S. Adolescent heroin use: a review of the descriptive and treatment literature. Journal of Substance abuse Treatment 2002;23(3):231‐7.
Hunt RD, Capper L, O'Connel P. Clonidine in child and adolescent psychiatry. Journal of Child Adolescent Psychofarmacology 1990;1:87‐102.
Kaminer Y. Pharmacotherapy for adolescents with psychoactive substance use disorders. NIDA Research Monograph 1995;156:291‐324.
Kleber HD, Riordan CE. The treatment of narcotic withdrawal: a historical review. Journal of Clinical Psichiatry 1982;43(6):30‐4.
Lipton DS, Maranda MJ. Detoxification from heroin dependency: an overview of method and effectiveness. Advances in Alcohol and Substance Abuse 1983;2(1):31‐55.
Marsch LA, Bickel WK, Badger GJ, Stothart ME. Comparison of pharmacological treatments for opioid dependent adoloscents. Archives of General Psychiatry 2005;62(10):1157‐64.
Mattick RP, Hall W. Are detoxification programmes effective?. Lancet 1996;347:97‐100.
Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet 1998;352(9128):609‐13.
Moher D, Cook DJ, Eastwood S, Olkin I, Drummond R, Stroup DF for the Quorum Group. Improving the quality of reports of metaanalyses of randomised controlled trials: the QUORUM statement. Lancet 1999;354(9193):1896‐900.
Monitoring the Future Study. Available at http://monitoringthefuture.orgAccessed 2006.
Nealgus A, Attilasoy A, Friedman SR, Andreade X, Miller M, Idelfonso G, et al. Trends in noninjected use of heroin and factors associated with the transitino to injecting. Heroin in the age of crack cocaine. Thousand Oaks, California: Inciardi JA, Herrison LD, 1998:131‐59.
Results from the 2002 National Survey on Drug use and health: National findings. Substance Abuse and Mental Health Services Admistration (SAMHSA). Office of Applied Studies, NHSDA series H‐22, DHHS publication n. SMA 03‐3836. Rockville, MD.
Schulz, KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12.
Valliant GE. What does long‐term follow‐up teach us about relapse and prevention of relapse in addiction?. British Journal of Addiction 1988;83:1147‐57.
